These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16944009)

  • 41. Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy.
    Mihm U; Gärtner BC; Faust D; Hofmann WP; Sarrazin C; Zeuzem S; Herrmann E
    J Hepatol; 2005 Aug; 43(2):217-24. PubMed ID: 15964093
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lamivudine treatment in patients with hepatitis B virus induced liver cirrhosis.
    Cetin K; Sabahattin K; Kadir D; Ahmet D; Ziyaettin D; Selim B; Mürüvvet B; Fatih B; Güngör B; Zeynel M; Yilmaz C; Atilla O
    Hepatogastroenterology; 2003 Dec; 50 Suppl 2():ccxcv-ccxcvii. PubMed ID: 15244206
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
    van Bömmel F; Zöllner B; Sarrazin C; Spengler U; Hüppe D; Möller B; Feucht HH; Wiedenmann B; Berg T
    Hepatology; 2006 Aug; 44(2):318-25. PubMed ID: 16871563
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
    Kazim SN; Chauhan R; Das BC; Sarin SK
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.
    Lampertico P; Viganò M; Manenti E; Iavarone M; Sablon E; Colombo M
    Gastroenterology; 2007 Nov; 133(5):1445-51. PubMed ID: 17983801
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine.
    Manolakopoulos S; Bethanis S; Koutsounas S; Goulis J; Vlachogiannakos J; Christias E; Saveriadis A; Pavlidis C; Triantos C; Christidou A; Papatheodoridis G; Karamanolis D; Tzourmakliotis D
    Aliment Pharmacol Ther; 2008 Feb; 27(3):266-73. PubMed ID: 17988233
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Therapeutic efficacy of lamivudine in patients with hepatitis B virus-related decompensated cirrhosis in Korea].
    Jung S; Suh DJ; Park HJ; Park YH; Song HG; Lee HC; Chung YH; Lee YS
    Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):418-27. PubMed ID: 12506246
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy.
    Di Marco V; Di Stefano R; Ferraro D; Almasio PL; Bonura C; Giglio M; Parisi P; Cappello M; Alaimo G; Craxì A
    Antivir Ther; 2005; 10(3):431-9. PubMed ID: 15918334
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation.
    Ben-Ari Z; Ashur Y; Daudi N; Shmilovitz-Wiess H; Brown M; Sulkes J; Klein A; Mor E; Tur-Kaspa R; Shouval D
    Clin Transplant; 2004 Aug; 18(4):415-22. PubMed ID: 15233819
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
    Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L
    Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection.
    Manolakopoulos S; Karatapanis S; Elefsiniotis J; Mathou N; Vlachogiannakos J; Iliadou E; Kougioumtzan A; Economou M; Triantos C; Tzourmakliotis D; Avgerinos A
    Am J Gastroenterol; 2004 Jan; 99(1):57-63. PubMed ID: 14687142
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
    Lampertico P; Invernizzi F; Viganò M; Loglio A; Mangia G; Facchetti F; Primignani M; Jovani M; Iavarone M; Fraquelli M; Casazza G; de Franchis R; Colombo M
    J Hepatol; 2015 Nov; 63(5):1118-25. PubMed ID: 26100495
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.
    Koffi J; Egounlety R; Pradat P; Lebosse F; Si-Ahmed SN; Lussier V; Chevallier P; Bailly F; Zoulim F
    Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):146-54. PubMed ID: 24025974
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The clinical meaning of the emergence of viral breakthrough during lamivudine treatment in patients with hepatitis B virus related chronic liver disease].
    Park CB; Lim HJ; Yun BC; Lee SU; Han BH
    Korean J Hepatol; 2004 Jun; 10(2):108-16. PubMed ID: 15218344
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of patients with decompensated HBV cirrhosis.
    Fontana RJ
    Semin Liver Dis; 2003 Feb; 23(1):89-100. PubMed ID: 12616454
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
    Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
    Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.
    Marrone A; Zampino R; Karayannis P; Cirillo G; Cesaro G; Guerrera B; Ricciotti R; del Giudice EM; Utili R; Adinolfi LE; Ruggiero G
    Aliment Pharmacol Ther; 2005 Oct; 22(8):707-14. PubMed ID: 16197491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.